The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction

Abstract

Switching therapy in eligible HFrEF patients from a RAS-blocker to sacubitril/valsartan induces beneficial reverse remodeling of both metrics of systolic as diastolic function.